AGREEMENTSchedule 13d Agreement • February 5th, 2015 • Children's Hospital of Philadelphia Foundation • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-l(k)(l) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Spark Therapeutics, Inc.
SPARK THERAPEUTICS, INC. CONFIDENTIALITY AGREEMENT August 26, 2015Confidentiality Agreement • July 5th, 2016 • Children's Hospital of Philadelphia Foundation • Biological products, (no disgnostic substances) • Pennsylvania
In connection with your status as holder of securities in Spark Therapeutics, Inc. (the “Company”), and as further contemplated by Section 3.2 of that certain Investors’ Rights Agreement, dated May 23, 2014 (the “Investors’ Rights Agreement”), among the Company and certain holders of the Company’s securities, you may have access to certain information concerning the business, financial condition, operations, assets and liabilities of the Company which is confidential non-public information. You and your trustees, officers, employees, agents and advisors (including, without limitation, attorneys, accountants, consultants, bankers and financial advisors) (collectively “Representatives”) agree to treat any information concerning the Company (whether prepared by the Company, its advisors or otherwise) that has been or is furnished or otherwise disclosed to you, in connection with your status as holder of Company securities on or prior to the date hereof, or in the future, in either case, b
